Physician

Devarajan P. Iyengar, M.D.

According to 2025 Medicare claims, Devarajan Iyengar, M.D. (NPI: 1689620700) practices internal medicine in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Hudson, NJ. This provider's primary affiliated billing organization is IYENGAR HEMATOLOGY ONCOLOGY MEDICAL CENTER PA (NPI: 1053441071) and primary practice location at 07002-4654.

Iyengar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 298 traditional Medicare patients, billed 85,904 HCPCS/CPT codes, and received $1,411,111 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 955 prescription claims across 122 beneficiaries totaling $1,218,950 in drug costs, led by Gammagard Liquid (Immun Glob G(Igg)/Gly/Iga Ov50). DME data shows 198 claims. Open Payments data shows 34 records totaling $676. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $834,017 to $1,411,111. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	347	62,704	$834,017
2016	334	56,792	$734,288
2017	301	44,952	$508,436
2018	282	56,073	$572,551
2019	295	55,858	$970,701
2020	322	68,354	$1,426,997
2021	335	86,793	$2,052,607
2022	314	116,842	$1,953,945
2023	324	118,136	$2,009,067
2024	298	85,904	$1,411,111

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	160	1,557	$2,022,200
2016	169	2,077	$3,698,331
2017	160	1,844	$3,253,981
2018	156	2,045	$3,931,974
2019	141	1,667	$3,875,853
2020	131	1,311	$2,840,189
2021	120	1,388	$2,712,140
2022	121	1,321	$2,548,465
2023	125	1,191	$2,193,934
2024	122	955	$1,218,950

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	173	$29,831
2016	N/R	198	$27,101
2017	N/R	N/R	N/R
2018	N/R	13	$2,239
2019	N/R	27	$1,662
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	22	$400
2023	N/R	N/R	N/R
2024	N/R	198	$123,158

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	97	235	$166
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	237	1,126	$114
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	179	927	$84
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	258	1,906	$8
36415	Insertion of needle into vein for collection of blood sample	253	1,578	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	21	544	$261,336
Lanreotide Acetate	Lanreotide Acetate	11	330	$89,513
Xgeva	Denosumab	25	738	$77,278
Ruxience	Rituximab-Pvvr	14	175	$75,062
Fulvestrant	Fulvestrant	11	330	$9,591

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4197	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, 74 to 100 grams of protein - premix	N	N/R	53	$102,952
B4224	Parenteral nutrition administration kit, per day	N	N/R	53	$9,164
B4185	Parenteral nutrition solution, not otherwise specified, 10 grams lipids	N	N/R	39	$8,357
B4220	Parenteral nutrition supply kit; premix, per day	N	N/R	53	$2,685

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	34	$676	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Devarajan P. Iyengar, M.D.?

Tedicare shows public-source Medicare data for Devarajan P. Iyengar, M.D. (NPI 1689620700), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Devarajan P. Iyengar, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Devarajan P. Iyengar, M.D.?

Devarajan P. Iyengar, M.D. is linked to IYENGAR HEMATOLOGY ONCOLOGY MEDICAL CENTER PA (billing NPI 1053441071) in the available physician profile data.

Does Devarajan P. Iyengar, M.D. have Open Payments data?

Devarajan P. Iyengar, M.D. has 34 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.